Developer docs
API playgroundTry for free, no card

Search company profiles

Animol Discovery

Full company profile

uuid0000va7

Namestring
Animol Discovery
Legal namestring
Animol Discovery, Inc.
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary drug discovery, DNA-encoded library screening, animal health pharmaceuticals, antiparasitic drug development, small molecule therapeutics
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Veterinary Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Veterinary Pharmaceutical Pipeline
TypeLicensing Royalties
Description

The company is building its own pipeline of proprietary veterinary small molecules and plans to advance them through clinical development. Revenue would likely come from eventual product sales or licensing agreements with larger animal health companies upon successful development and regulatory approval.

animol-discovery.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Animol Discovery is a biopharmaceutical company that discovers and develops proprietary small molecule veterinary pharmaceuticals for companion and farm animals. The company combines genomics analysis, DNA-encoded library screening, AI/machine learning, and computational chemistry to identify novel active pharmaceutical ingredients, building a pipeline that spans antiparasitics to chronic disease treatments. Revenue is intended to come from eventual licensing of developed compounds to larger animal health companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Novel drug-like compounds identified in weeks from initial DEL screen
+1 more record
Product overview1 text field

Animol Discovery operates a proprietary drug discovery platform for veterinary pharmaceuticals, combining DNA-encoded library (DEL) technology, artificial intelligence/machine learning, and computational chemistry to identify novel small molecule active pharmaceutical ingredients for companion and farm animals. The company is building its own pipeline of veterinary small molecules spanning anti-parasitics to chronic diseases, but no named commercial products have been launched yet. All discovery activities are conducted through their integrated technology platform rather than discrete product modules.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Biotechnology Partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2019-01-01
Description

The Animol team is supported by best-in-class biotechnology partners and an extensive network of industry experts and scientists for their drug discovery platform.

animol-discovery.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major global animal health company offering parasiticides, vaccines, and therapeutics for both companion and production animals. Comparable as an incumbent acquirer with overlapping antiparasitic and chronic disease franchises and as a former employer of multiple Animol team members.

TypeBroad incumbent
Description

Diversified animal health and mineral nutrition company with significant parasiticides, vaccines, and specialty pharmaceuticals for livestock and companion animals. Comparable as an incumbent with overlapping antiparasitic and production animal focus.

3Aratana Therapeutics
TypeDirect peer
Description

Animal health biopharmaceutical company that developed novel therapeutics for companion animals before being acquired by Elanco. Direct comparability as a venture-backed veterinary biotech pursuing proprietary small molecules and biologics across similar indication areas.

TypeBroad incumbent
Description

Specialty veterinary pharmaceuticals company focused on companion animal therapeutics across endocrinology, dermatology, and critical care. Comparable as a mid-sized acquirer of late-stage veterinary assets and as a potential strategic partner for Animol's chronic disease programs.

5Invetx
TypeDirect peer
Description

Biotechnology company developing novel, species-specific monoclonal antibody therapeutics for animal health. Closest direct peer in terms of being a venture-backed, platform-driven animal health biotech pursuing differentiated veterinary biologics; raises and deploys capital in a comparable way to Animol.

TypeEmerging player
Description

Specialty CDMO and animal health drug developer with proprietary reformulations and combination products for veterinary use. Comparable as a development-stage animal health company turning proprietary technology into licensing transactions with larger animal health partners.

TypeBroad incumbent
Description

Largest global animal health company with a broad portfolio of veterinary pharmaceuticals, biologics, diagnostics, and parasiticides across companion and farm animals. Direct comparability as the dominant acquirer/licensee of veterinary small molecules, and home to several Animol board members and SAB contacts.

TypeBroad incumbent
Description

Animal health-focused specialty company with operations across pharmaceuticals, diagnostics, and medtech for veterinary markets. Comparable as an active consolidator in veterinary pharma and a plausible licensing or M&A counterparty for Animol's pipeline.

TypeEmerging player
Description

Agtech startup applying DNA-encoded library screening and AI/ML to discover safe and effective crop protection chemistries. Sister portfolio company of Anterra Capital using the same discovery playbook as Animol; provides a directly comparable model for the platform's commercial trajectory.

10Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Top-five animal health company with leading parasiticides (e.g., NexGard) and a strong veterinary pharmaceuticals pipeline. Direct comparability as a likely licensing/strategic partner for Animol's antiparasitic and chronic disease assets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Animol Discovery

Veterinary Pharmaceuticalsanimol-discovery.com

Animol Discovery firmographics

Firmographics
Name
Animol Discovery
Legal name
Animol Discovery, Inc.
Website
https://animol-discovery.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Animol Discovery industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Veterinary drug discovery
  • DNA-encoded library screening
  • Animal health pharmaceuticals
  • Antiparasitic drug development
  • Small molecule therapeutics

Where Animol Discovery is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Animol Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Veterinary Pharmaceutical Pipeline: The company is building its own pipeline of proprietary veterinary small molecules and plans to advance them through clinical development. Revenue would likely come from eventual product sales or licensing agreements with larger animal health companies upon successful development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Animol Discovery product offering

Product offering

Core offering

Animol Discovery is a biopharmaceutical company that discovers and develops proprietary small molecule veterinary pharmaceuticals for companion and farm animals. The company combines genomics analysis, DNA-encoded library screening, AI/machine learning, and computational chemistry to identify novel active pharmaceutical ingredients, building a pipeline that spans antiparasitics to chronic disease treatments. Revenue is intended to come from eventual licensing of developed compounds to larger animal health companies.

Product overview

Animol Discovery operates a proprietary drug discovery platform for veterinary pharmaceuticals, combining DNA-encoded library (DEL) technology, artificial intelligence/machine learning, and computational chemistry to identify novel small molecule active pharmaceutical ingredients for companion and farm animals. The company is building its own pipeline of veterinary small molecules spanning anti-parasitics to chronic diseases, but no named commercial products have been launched yet. All discovery activities are conducted through their integrated technology platform rather than discrete product modules.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Novel drug-like compounds identified in weeks from initial DEL screen
  • +1 more outcomes

Companies that use Animol Discovery

Customer profile

Segments2 records

Ideal customer profiles1 record

Animol Discovery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Animol Discovery partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Biotechnology PartnerssupportingTechnology or Integration · 1 January 2019The Animol team is supported by best-in-class biotechnology partners and an extensive network of industry experts and scientists for their drug discovery platform.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Animol Discovery competitors and assessment

Company assessment

Broad incumbents

  • Elanco Animal Health: Major global animal health company offering parasiticides, vaccines, and therapeutics for both companion and production animals. Comparable as an incumbent acquirer with overlapping antiparasitic and chronic disease franchises and as a former employer of multiple Animol team members.
  • Phibro Animal Health: Diversified animal health and mineral nutrition company with significant parasiticides, vaccines, and specialty pharmaceuticals for livestock and companion animals. Comparable as an incumbent with overlapping antiparasitic and production animal focus.
  • Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company focused on companion animal therapeutics across endocrinology, dermatology, and critical care. Comparable as a mid-sized acquirer of late-stage veterinary assets and as a potential strategic partner for Animol's chronic disease programs.
  • Zoetis: Largest global animal health company with a broad portfolio of veterinary pharmaceuticals, biologics, diagnostics, and parasiticides across companion and farm animals. Direct comparability as the dominant acquirer/licensee of veterinary small molecules, and home to several Animol board members and SAB contacts.
  • Vimian Group: Animal health-focused specialty company with operations across pharmaceuticals, diagnostics, and medtech for veterinary markets. Comparable as an active consolidator in veterinary pharma and a plausible licensing or M&A counterparty for Animol's pipeline.
  • Boehringer Ingelheim Animal Health: Top-five animal health company with leading parasiticides (e.g., NexGard) and a strong veterinary pharmaceuticals pipeline. Direct comparability as a likely licensing/strategic partner for Animol's antiparasitic and chronic disease assets.

Direct peers

  • Aratana Therapeutics: Animal health biopharmaceutical company that developed novel therapeutics for companion animals before being acquired by Elanco. Direct comparability as a venture-backed veterinary biotech pursuing proprietary small molecules and biologics across similar indication areas.
  • Invetx: Biotechnology company developing novel, species-specific monoclonal antibody therapeutics for animal health. Closest direct peer in terms of being a venture-backed, platform-driven animal health biotech pursuing differentiated veterinary biologics; raises and deploys capital in a comparable way to Animol.

Emerging players

  • Kindeva Drug Delivery: Specialty CDMO and animal health drug developer with proprietary reformulations and combination products for veterinary use. Comparable as a development-stage animal health company turning proprietary technology into licensing transactions with larger animal health partners.
  • Enko Chem: Agtech startup applying DNA-encoded library screening and AI/ML to discover safe and effective crop protection chemistries. Sister portfolio company of Anterra Capital using the same discovery playbook as Animol; provides a directly comparable model for the platform's commercial trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Animol Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Animol Discovery leadership team

Management profile

Number of profiles

Profiles11 records

Animol Discovery funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Animol Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Animol Discovery

What does Animol Discovery do?

Animol Discovery is a biopharmaceutical company that discovers and develops proprietary small molecule veterinary pharmaceuticals for companion and farm animals. The company combines genomics analysis, DNA-encoded library screening, AI/machine learning, and computational chemistry to identify novel active pharmaceutical ingredients, building a pipeline that spans antiparasitics to chronic disease treatments. Revenue is intended to come from eventual licensing of developed compounds to larger animal health companies.

Is Animol Discovery a public or private company?

Animol Discovery is a private company. It is classified as venture growth investor backed and is currently operating.

When was Animol Discovery founded?

Animol Discovery was founded in 2020. It employs 11 to 50 people.

Where is Animol Discovery based?

Animol Discovery is headquartered in Boston, United States, in the North America region.

How does Animol Discovery make money?

One revenue line is on record: veterinary Pharmaceutical Pipeline.

Who are Animol Discovery's main competitors?

Broad incumbents on record are Elanco Animal Health, Phibro Animal Health, Dechra Pharmaceuticals, Zoetis, Vimian Group and Boehringer Ingelheim Animal Health. Direct peers are Aratana Therapeutics and Invetx. Emerging players are Kindeva Drug Delivery and Enko Chem.

Does Animol Discovery have an API?

No public API is recorded for Animol Discovery.

What industry is Animol Discovery in?

Animol Discovery's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DAnimol Discovery, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The company disclosed that it raised approximately $4 million from one investor, with no sales commissions or finder's fees incurred during the transaction. This filing serves as a regulatory notice of the private capital raise rather than a public market event.SecSEC FORM DAnimol Discovery, Inc. filed a Form D with the Securities and Exchange Commission for an exempt offering of securities under Rule 506(b). The filing indicates that the company raised approximately $32 million from three investors, with no sales commissions or finder's fees incurred. The offering was signed by CEO Andrew Plant on August 1, 2022.Business Wire BlogAnimol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary PharmaceuticalsAnimol Discovery raised $34 million in Series B financing led by Novalis LifeSciences, with participation from Finistere Ventures and Anterra Capital. The company will use the funds to advance its pipeline of novel veterinary pharmaceuticals. Marijn Dekkers and Doug Hutchens joined the board and as chief scientific officer.Business Wire BlogAnimol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary PharmaceuticalsAnimol Discovery raised $34.0 million in Series B financing led by Novalis LifeSciences, with participation from Finistere Ventures and Anterra Capital. The funds will advance its pipeline of novel veterinary pharmaceuticals, and Marijn Dekkers and Doug Hutchens joined the board.Venture Capital Access OnlineAnimol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary PharmaceuticalsAnimol Discovery, Inc. announced the closing of a $34.0 million Series B financing round led by Novalis LifeSciences LLC, with participation from Finistere Ventures and Anterra Capital. The company also appointed Marijn Dekkers to its Board of Directors and Doug Hutchens as Chief Scientific Officer to advance its pipeline of novel veterinary pharmaceuticals using DNA-encoded library technology.Business Wire BlogAnimol Discovery, Inc. annonce un financement de série B de 34 millions de dollars, visant à faire progresser son pipeline de médicaments vétérinaires novateursAnimol Discovery, Inc. has raised $34 million in a Series B funding round led by Novalis LifeSciences LLC to advance its pipeline of innovative veterinary drug candidates. The company plans to utilize the capital to expand clinical development and enhance its proprietary drug discovery platform, which combines DNA-encoded libraries with machine learning. Additionally, Marijn Dekkers will join the board of directors and Doug Hutchens will serve as chief scientific officer.Animol-DiscoveryNews – Animol DiscoveryAnimol Discovery, Inc. announced it has raised $34.0 million in Series B financing led by Novalis Lifesciences to advance its veterinary pharmaceutical pipeline. The company also appointed Marijn Dekkers and Michelle Haven to its Board of Directors, along with Douglas Hutchens as Chief Scientific Officer. These moves aim to leverage the company's DNA-encoded library technology for discovering novel drugs in the $40 billion animal health market.